• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives » Picking your poison: Wall Street or Venture Capital?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Picking your poison: Wall Street or Venture Capital?

Aug. 21, 2011
By Mark McCarty

Life is full of choices, not all of them pleasant. For device makers of late, this definitely holds true.

Firms in the venture capital end of things are not necessarily worried that VC has utterly abandoned med-tech, but it would appear that the start-up might find the going tough, even though firms with a little more development are getting more love from investors. As my colleague Amanda Pedersen noted in Medical Device Daily recently, a recent report by CB Insights (New York) indicates that the number of VC deals for med-tech continues to tail off, dropping from 184 in the third quarter of 2010 to 147 in the second quarter of this year. This despite the fact that investors dropped $1.9 billion into med-tech in the second quarter. Amanda's coverage appeared in the July 22 edition of MDD.

The problem for small firms is confirmed by a MoneyTree report published earlier this month, which states that in the just-completed second quarter, only 44 start-up med-tech companies managed to win over investors, a 27% drop over the same quarter in 2010. While this report also notes that more money is going into med-tech, it's not new money. Med-tech exits are accounting for a larger share of the cash plowed into med-tech firms, which means that VC firms are having a tougher time getting new investors on board.

Is Wall Street any better off? Depends on whom you ask. According to an Aug. 9 story in the Wall Street Journal, this summer isn't even remotely reminiscent of Valentine's Day for large device makers. The story states that big-time device firms such as Medtronic (Fridley, Minnesota) are taking a pounding on Wall Street over concerns about the device tax, the cuts in reimbursement due to healthcare reform law, and price pressures from payers of all stripes.

There have been a number of acquisitions lately, such as the Johnson & Johnson (J&J; Brunswick, New Jersey) buyout of Synthes (Solothurn, Switzerland), which rang in at $21 billion, a sum that dwarfs the recently announced buy-out of Motorola (Schaumberg, Illinois) by Google (Mountain View, California), but it's not often that med-tech acquisitions are larger than those in the various segments of the IT industry.

On the other hand, the established firms aren't doing so well in terms of market cap. Edwards Lifesciences (Irvine, California) has not done well since the July advisory committee, and its shares are still going for less than $70 a share after hitting more than $90 earlier this year, while Medtronic's stocks are going for about $31 despite having hit more than $42 earlier this summer.

Okay, so it's not the summer of love for med-tech. Still, it's the summer doldrums, and a little distance from the debt ceiling mess might shore up a lot of things in the global economy, not just the fortunes of med-tech firms. The message here, basically, is stay tuned. There's a lot more to come.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe